Yasmin Geiger1, Marganit Gonen-Shahar2, Gabriel Vainstein3, Angela Ruban2, and Assaf Tal1
1Weizmann Institute of Science, Rehovot, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Maccabi Healthcare, Kefar Sava, Israel
Synopsis
Attention deficit hyperactivity disorder (ADHD) is
a neurodevelopmental disorder characterized by irregular levels of
hyperactivity, impulsivity and inattention. It is commonly linked to
dopamine and norepinephrine balance. Several studies suggested connections to γ-amino
butyric acid (GABA) and glutamate (Glu) imbalance in the dorsal anterior
cingulate cortex (dACC). Here we use 1H-MRS to study GABA and glutamate
+ glutamine (Glx) levels in the dACC of ADHD patients, before and after pharmacological
treatment and compared to healthy adults. We found no metabolic difference
between ADHD and control group and no change after amphetamine treatment. We
found no metabolic correlation to ADHD scores.
Introduction
Attention deficit hyperactivity
disorder (ADHD) is a common neurodevelopmental disorders with prevalence rates
of 7.2 %[1]. The cingulo-frontal-parietal (CFP) network
is responsible for executive functioning and displays functional abnormalities
in ADHD patients [2]. ADHD is commonly linked to dopamine and
norepinephrine deficiency [3]. ADHD symptoms can be reduced using methylphenidate
(such as Ritalin) or amphetamine (as Adderall) based medication which target
dopamine transporters. Recent studies show GABA and Glutamate are disturbed
across the CFP network in subjects with ADHD [4-7].
However, these results are inconsistent. Showing changes in one metabolic
system but not the other or no changes to GABA or Glx. The dorsal anterior
cingulate cortex (dACC), part of the CFP network, is responsible for decision
making and allocation of cognitive control [8]. Here we examine metabolic changes, induced
by Adderall, at the dACC of ADHD patient compared to healthy adults using 1H-MRS
in 3T MRI scanner.Methods
Cohort:
12
adults (5F, age 25.1 ± 3.1, mean ± standard
deviation) diagnosed with ADHD by neurologist
and treated medically with amphetamines (Adderall) and 10 healthy adults (6F, age 25.6 ± 3.4, mean ±
standard deviation) enrolled from the Maccabi Health
Services database and gave informed
consent.
ADHD patients withheld stimulant
medication three days prior to the MRS
scan. Scores of inattention (IA) and hyper-activity
(HA) were assessed for all volunteers, based on self-reported questionnaires (ASRS
and DSM). Exclusion criteria included current use of neurological or
psychiatric medication. Control volunteers with IA or HA scores > 16 (ASRS)
or > 5 (DSM) were excluded.
MRI and MRS: Scans were carried out on Siemens 3-T Prisma
(Siemens-Healthineers, Erlangen, Germany) using 32-channel coil. Structural
images were acquired using sagittal magnetization prepared rapid gradient echo
(MPRAGE) sequence. 1H‑MRS spectra were acquired from 10 mL voxel at
the dACC. Spectra were acquired using MEGAPRESS [9, 10],
with TR/TE = 3000/68 ms and 14 ms sinc-Gaussian editing pulses applied
interleaved at 7.5 ppm and 1.9 ppm and 192 scans (TA=9:48 min). ADHD patients were initially scanned after three
days without pharmacological treatment, and then removed from the magnet,
administered 10 ms of Adderall, and rescanned after 90 minutes. The scanning
protocol was identical for both scans.
Post-processing: 1H-MRS Spectra, fitting and voxel
placement are in figure 2. GABA+ concentrations calculated using
double-Gaussian fitting to the 3.0 ppm resonance in the MEGAPRESS difference
spectra, using in-house routines written (VDI software, The Weizmann
Institute, Israel; www.vdisoftware.net
) in MATLAB 2020a (The Mathworks, Natick MA).
Additional metabolic concentrations were derived from the un-edited MEGAPRESS,
using LCModel v6.3 [13] with a simulated basis set containing 16 metabolites.
Concentrations with CRLB<15% were discarded. Metabolic concentrations were
corrected for partial volume effect [122, 123].Results
GABA, Glx (Glu+Gln), Cr, NAA, Cho and
mI concentrations were analyzed and correlated to IA and HA scores. In the ADHD
group we found no change in the concentration of any metabolite after
administration/consumption of Adderall (10 mg) using t-test analysis. No
significant difference in concentrations were observed between ADHD and control
group. No linear correlations were observed between metabolic concentrations
and ASRS or DSM scores for inattention and hyper-activity. Discussion and Conclusion
We found no changes to GABA, Glx or
their ratio in the dACC of ADHD patients compared with healthy volunteers.
Intra-subject analysis did not show any effect of amphetamine on metabolites
concentrations. Our preliminary results are similar to the results of a large
meta-analysis and clinical studies that did not find any difference in
neurotransmitters concentration in the dACC between ADHD patients and control [11-14].Acknowledgements
Assaf Tal acknowledges
the support of the Israeli Science Foundation (personal grant 416/20), the
Monroy‐Marks Career Development Fund, and the historic generosity of the Harold
Perlman FamilyReferences
- Thomas,
R., et al., Prevalence of attention-deficit/hyperactivity
disorder: a systematic review and meta-analysis. Pediatrics, 2015. 135(4): p. e994-e1001.
- Bauer,
J., et al., Hyperactivity and impulsivity
in adult attention-deficit/hyperactivity disorder is related to glutamatergic
dysfunction in the anterior cingulate cortex. The World Journal of
Biological Psychiatry, 2018. 19(7):
p. 538-546.
- Mamiya,
P.C., A.B. Arnett, and M.A. Stein, Precision
medicine care in ADHD: The case for neural excitation and inhibition. Brain
Sciences, 2021. 11(1): p. 91.
- Maltezos,
S., et al., Glutamate/glutamine and
neuronal integrity in adults with ADHD: a proton MRS study. Translational
psychiatry, 2014. 4(3): p.
e373-e373.
- Naaijen,
J., et al., Fronto-striatal glutamatergic
compounds in compulsive and impulsive syndromes: a review of magnetic resonance
spectroscopy studies. Neuroscience & Biobehavioral Reviews, 2015. 52: p. 74-88.
- Edden,
R.A., et al., Reduced GABA concentration
in attention-deficit/hyperactivity disorder. Archives of general psychiatry,
2012. 69(7): p. 750-753.
- Mamiya,
P.C., et al., Task-related
excitatory/inhibitory ratios in the fronto-striatal circuitry predict attention
control deficits in attention-deficit/hyperactivity disorder. medRxiv,
2021.
- Shenhav,
A., J.D. Cohen, and M.M. Botvinick, Dorsal
anterior cingulate cortex and the value of control. Nature neuroscience,
2016. 19(10): p. 1286-1291.
- Tremblay,
S., et al., The Use of Magnetic Resonance
Spectroscopy as a Tool for the Measurement of Bi-hemispheric Transcranial
Electric Stimulation Effects on Primary Motor Cortex Metabolism.
Jove-Journal of Visualized Experiments, 2014(93).
- Marjanska,
M., et al., Brain dynamic neurochemical
changes in dystonic patients: a magnetic resonance spectroscopy study. Mov
Disord, 2013. 28(2): p. 201-9.
- Maier,
S., et al., Effects of 12-Week
Methylphenidate Treatment on Neurometabolism in Adult Patients with ADHD: The
First Double-Blind Placebo-Controlled MR Spectroscopy Study. Journal of
Clinical Medicine, 2020. 9(8): p.
2601.
- Endres,
D., et al., Normal neurochemistry in the
prefrontal and cerebellar brain of adults with attention-deficit hyperactivity
disorder. Frontiers in behavioral neuroscience, 2015. 9: p. 242.
- Schür,
R.R., et al., Brain GABA levels across
psychiatric disorders: A systematic literature review and meta‐analysis of
1H‐MRS studies. Human brain mapping, 2016. 37(9): p. 3337-3352.
- Perlov,
E., et al., Spectroscopic findings in
attention-deficit/hyperactivity disorder: review and meta-analysis. The
World Journal of Biological Psychiatry, 2009. 10(4-2): p. 355-365.